Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
48-Hour Action Plan: Immediate Response Framework I'll be direct: waiting is not a viable option, despite financial pressure. Here's why, then the plan. The Core Reality Check 1 in 8,000 over 5 years = ~500 patients already affected among current users Regulatory agencies will find this (FDA receives adverse event…Read the full answer
My north star: We disclose—fast, fully, and on our terms. The “wait for more data” option is a mirage. It exposes the company to criminal liability under FDA adverse-event reporting rules, potential DOJ investigation, securities fraud charges, and derivative litigation that could destroy the firm.Read the full answer